Scientific and Regulatory Policy Committee Points to Consider*: Approaches to the Conduct and Interpretation of Vaccine Safety Studies for Clinical and Anatomic Pathologists.


Journal

Toxicologic pathology
ISSN: 1533-1601
Titre abrégé: Toxicol Pathol
Pays: United States
ID NLM: 7905907

Informations de publication

Date de publication:
02 2020
Historique:
pubmed: 9 10 2019
medline: 5 6 2021
entrez: 10 10 2019
Statut: ppublish

Résumé

The design and execution of toxicology studies supporting vaccine development have some unique considerations relative to those supporting traditional small molecules and biologics. A working group of the Society of Toxicologic Pathology Scientific and Regulatory Policy Committee conducted a review of the scientific, technical, and regulatory considerations for veterinary pathologists and toxicologists related to the design and evaluation of regulatory toxicology studies supporting vaccine clinical trials. Much of the information in this document focuses on the development of prophylactic vaccines for infectious agents. Many of these considerations also apply to therapeutic vaccine development (such as vaccines directed against cancer epitopes); important differences will be identified in various sections as appropriate. The topics addressed in this

Identifiants

pubmed: 31594486
doi: 10.1177/0192623319875085
doi:

Substances chimiques

Vaccines 0

Types de publication

Guideline Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

257-276

Auteurs

Rani S Sellers (RS)

Pfizer Inc, Pearl River, New York, NY, USA.

Keith Nelson (K)

Charles River Laboratories, Mattawan, MI, USA.

Bindu Bennet (B)

Janssen Research & Development LLC, Spring House, PA, USA.

Jayanthi Wolf (J)

Merck & Co, Inc, West Point, PA, USA.

Niraj Tripathi (N)

Covance, Madison, WI, USA.

Ronnie Chamanza (R)

Janssen Pharmaceutical Companies of Johnson & Johnson, Beerse, Belgium.

Marie-France Perron Lepage (MF)

Charles River Laboratories, St-Germain-Nuelles, France.

Karissa Adkins (K)

Sanofi US, Framingham, MA, USA.

Sebastien Laurent (S)

Sanofi R&D, Preclinical Safety Department, Montpellier, France.

Sean P Troth (SP)

Merck & Co, Inc, West Point, PA, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH